On March 24, 2026, Karyopharm Therapeutics Inc. entered a Securities Purchase Agreement to sell around 1 million shares of common stock at about $6.785 each, aiming for $30 million in proceeds for corporate needs and clinical trials. Additionally, if all warrants are exercised, total gross proceeds could reach approximately $74 million.